Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms
Reduce development timelines and costs, while improving access to life-saving treatments
VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka Health"), has been selected by OneMedNet Corporation (Nasdaq: ONMD) to lead a high-impact data analytics initiative focused on improving how cancer therapies are brought to market. The project focuses on leveraging OneMedNet’s regulatory-grade patient data including Radiology Imaging data to develop external control arms (ECAs), which has the potential to be a faster, more cost-effective alternative to traditional clinical trials. This approach offers a potentially smarter way to generate clinical evidence by leveraging existing patient data, thereby possibly accelerating treatment access and reducing the need for costly, time-consuming trials. The initiative also provides both organizations with exposure to the rapidly expanding Real-World Evidence (RWE) market is projected to exceed $4.6 billion1 globally by 2030.
This strategic project reflects growing momentum behind real-world data (RWD) as a critical component of next-generation evidence generation for cancer therapeutics2. OneMedNet’s iRWD Real-World Data platform and federated provider network offers regulatory-grade, diverse, and longitudinal datasets, making it uniquely suited to drive Real-World Evidence (RWE) studies and accelerate healthcare innovation.
The multi-phase project is intended to showcase how OneMedNet’s oncology dataset can be used to replicate the results of traditional clinical trials, without the same time, cost, and complexity as traditional trials. By offering a faster and more efficient path to generate the evidence needed for regulatory and reimbursement approvals, this initiative can potentially help accelerate market entry for new cancer therapies, particularly in areas of high unmet needs like colorectal cancer.
Inka Health plans to deploy its proprietary SynoGraph platform, which combines machine learning with causal inference methods, to build and validate an ECA for the Keynote-189 trial3 of pembrolizumab in non-small cell lung cancer aligned with regulatory and Health Technology Assessment (HTA) best practices, including those from the FDA, European Medicines Agency (EMA), and National Institute for Health and Care Excellence (NICE). The initial focus will be on non-small cell lung cancer (NSCLC), a prevalent and clinically significant cancer type where real-world insights can meaningfully improve both patient access to therapies and regulatory confidence.
“We selected Inka Health for this initiative because their methodological approach aligns perfectly with our vision for high-quality evidence generation,” said Aaron Green, President & CEO of OneMedNet. “Their ability to apply rigorous, AI-driven analytics to our regulatory-grade, diverse datasets makes them the ideal partner to showcase how OneMedNet’s Real-World Data can be used as a trusted external control arm in oncology research—with the potential to help pharmaceutical companies realize a stronger ROI on clinical development and driving broader adoption among CROs and life sciences organizations looking for faster, more cost-effective trial alternatives.”
The collaboration is expected to result in a scientific abstract for submission to ISPOR Europe 2025, reinforcing Inka Health’s leadership in applying artificial intelligence and real-world data to oncology research. As ECAs become increasingly prominent in global drug development strategies, this project positions Onco and its subsidiary at the forefront of how industry brings new therapies to patients.
“This collaboration is about more than applying advanced analytics to oncology data. It's about reshaping how we generate credible evidence for regulatory and reimbursement decisions using real-world patients, not just trial participants. With SynoGraph, we’re aiming to set a new bar for how external control arms can be built and trusted,” said Paul Arora, Co-Founder of Inka Health.
About OneMedNet
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,750 healthcare sites through its iRWD™ platform. This isn’t just data, it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities, rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at .
About Inka Health
Inka Health is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI. Its proprietary platform, SynoGraph, leverages AI-powered causal inference to identify which cancer patients are most likely to respond to specific treatments, advancing precision medicine. By integrating diverse multimodal medical data—including genomics, transcriptomics, and proteomics—SynoGraph uncovers hidden insights that can optimize treatment decisions and clinical trial design. With this cutting-edge technology, Inka Health aims to help pharmaceutical companies accelerate drug development, reduce trial failures, and bring life-saving therapies to market faster.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
“Thomas O’Shaughnessy”
Chief Executive Officer
For more information, please contact:
Thomas O’Shaughnessy
Chief Executive Officer
Tel: 5
OneMedNet Contacts:
Michael Wong, VP Marketing
Email:
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
1 Real World Evidence Solutions Market –
2 Wang X, Dormont F, Lorenzato C, et al. Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016–2021. J Cancer Policy. 2023;35:100403.
3
